#menstrualmigraine
#AbbVie's #Qulipta has become the first #oralCGRPinhibitor to show efficacy in a phase 3 study involving #women with #menstrualmigraine, which is severe and tends to resist current treatments.

buff.ly/GKTMra6
AbbVie charts a new course for CGRPs in menstrual migraine
Newsletters and Deep Dive digital magazine
pharmaphorum.com
September 11, 2026 at 11:45 AM